I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Graves\' disease (GD) is an autoimmune disorder, clinically presenting as hyperthyroidism, diffuse thyroid enlargement with or without ophthalmopathy and occasionally dermopathy.\[[@ref1]\] Cause of GD is multifactorial with contribution of genetic and environmental factors.\[[@ref2][@ref3][@ref4]\] Protein tyrosine phosphatase nonreceptor 22 (*PTPN22*) gene helps to prevent hyperresponsiveness of T cells via a protein it encodes \[known as lymphoid tyrosine phosphatase (LYP) protein\], which causes negative T cell regulation.\[[@ref5]\] Among several single-nucleotide polymorphisms (SNPs) in *PTPN22* gene, 1858 C/T (Arg620Trp) is an important SNP. Initial studies showed Type 1 diabetes be associated with *PTPN22* Arg620Trp SNP, where T allele acted as a risk allele.\[[@ref6]\] Later, T allele of this SNP was shown to be associated with many other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus in addition to GD.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]\] Ichimura *et al*. did not find an association between *PTPN22* 1858 C/T SNP and GD susceptibility in Japanese population, suggesting that it does not play a causal role for its development.\[[@ref14]\] Variations in the results from different studies could predominantly be due to distinct ethnicities of the studied populations. It would be useful to study populations having distinct ethnic background. As no study on the role of *PTPN22* 1858 C/T SNP in GD predisposition has been conducted till date in our population, using a conventional polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach, we studied the association between 1858 C/T polymorphism and GD in Kashmiri population.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

A total of 135 patients with GD (33 men and 102 women) between the age of 14 and 68 years (average = 37.97 years) were enrolled in this study. Diagnosis of GD was established on the basis of clinical parameters of thyrotoxicosis (history of marked weight loss, presence of diffuse goiter, presence of skin or eye changes) that diffusely increased Technetium^99m^ pertechnetate uptake on thyroid scintigraphy and positive thyroid stimulating hormone (TSH) receptor antibody.

Information was collected on the patient\'s age at onset, history of smoking, size of thyroid gland, presence of thyroid eye disease, serum thyroid hormone levels and antibody titers of TSH receptor antibodies. A group of 150 age- and sex-matched healthy volunteers (42 men and 108 women), who were euthyroid and had no personal or family history of Grave\'s or other autoimmune diseases, served as controls. Informed consent was obtained from each individual who participated in the study. The frequency distribution, demographics, and risk factors in patients with GD and controls are shown in [Table 1](#T1){ref-type="table"}.

###### 

Frequency distribution of demographic factors, genotypic and allelic frequencies of PTPN22 1858 C/T polymorphism in patients with GD and controls
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Sample collection and molecular analysis {#sec2-1}
----------------------------------------

Five milliliters of peripheral blood were collected from GD patients and healthy controls in ethylenediaminetetraacetic acid containing tubes. DNA was isolated using HiPurA™ Blood Genomic DNA Miniprep Purification Kit (HiMedia Laboratories Pvt. Ltd., Mumbai, India).

Amplification of the exon 1858 C/T *PTPN22* gene {#sec2-2}
------------------------------------------------

PCR amplification was carried out using a single set of the primer pair (Forward = ACTGATAATGTTGCTTCAACGG; Reverse = TCACCAGCTTCCTCAACCAC) that amplified the exonic region *PTPN22* gene containing the 1858 C/T polymorphic site. The amplicon size was 218bp. PCR was carried out in a final volume of 25 μl containing 50 ng genomic DNA template, 1X PCR buffer (Biotools, B and M Labs, S.A. Madrid-Spain) with 2 mM MgCl~2~, 0.4 mM of each primer (Sigma-Aldrich Co. LLC, USA), 50 mM dNTPs (Biotools, B and M Labs, S.A. Madrid-Spain), and 1U DNA polymerase (Biotools, B and M Labs, S.A. Madrid-Spain). For PCR amplification, the standard program was used as follows: one initial denaturation step at 94°C for 5 min, followed by 30 denaturation cycles of 30 s at 94°C, 30 s of annealing at 62°C, and 60 s of extension at 72°C, followed by a final elongation cycle at 72°C for 5 min.

Genotypic analysis of PTPN22 1858 C/T polymorphism by RFLP {#sec2-3}
----------------------------------------------------------

The PCR product of 218bp \[[Figure 1](#F1){ref-type="fig"}\] containing the 1858 C/T restriction site was digested by enzyme RsaI (Fermentas Thermo Fisher Scientific Inc., Massachusetts, USA). Products were resolved on 3% Agarose gel. *PTPN22* 1858C allele if present is recognized as a cleavage site by endonuclease RsaI. The 1858T allele is not digested and yields one fragment of 218 bp, while the 1858C allele is digested and yields two fragments of 176 and 46 bp and the heterozygous C/T gives three bands of 218, 176, and 46 bp \[[Figure 2](#F2){ref-type="fig"}\].

![Representative gel picture showing *PTPN22* 1858 amplicon.](IJEM-22-457-g002){#F1}

![Representative gel picture showing RFLP analysis of *PTPN22* 1858 PCR product](IJEM-22-457-g003){#F2}

Laboratory tests {#sec2-4}
----------------

Blood samples were collected from each patient in the fasting state. Serum concentrations of TSH, total T3, and total T4 were measured by commercial chemiluminescent immunoassays (Beckman Coulter Unicel DXI 800 Access Immunoassay System, Brea, California). TSH receptor antibody was measured by enzyme-linked immunosorbent assay (Elisa RSR^™^ TRAb second-generation kit; RSR, Cardiff, UK). The normal values were as follows: TSH, 0.5--6.5 mIU/ml; total T3, 0.70--2.50 ng/ml; total T4, 4.0--13.0 mcg/dl, and TRAb ≤ 1U/l.

Statistical analysis {#sec2-5}
--------------------

For statistical analysis, the genotype and allelic frequency distributions of polymorphisms in the control and GD patient groups were compared using the χ^2^-test. When the assumption of the χ^2^-test was violated (i.e., when one cell had an expected count of \<1, or \>20% of the cells had an expected count of \<5), Fisher\'s exact test was used. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined for the disease susceptibility of specific genotypes and alleles. Results were considered statistically significant when the probability of findings occurring by chance was \<5% (*P* \< 0.05).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 285 individuals (135 GD cases and 150 healthy controls) were included in this study. The distribution of *PTPN22* 1858genotypic and allelic frequencies in cases and controls is given in [Table 1](#T1){ref-type="table"}. Among the patients with GD, the frequencies of *PTPN22* 1858 CC, CT and TT genotypes were 132 (97.78%), 3 (2.22%), and 0 (0%), respectively, whereas every healthy control had a positive CC genotypes. None among controls was positive for CT and TT genotypes. Statistical analysis indicated that genotypic and allelic frequencies of the *PTPN22* 1858 polymorphism in cases and controls did not differ significantly (*P* \> 0.05).

Furthermore, the association between *PTPN22* 1858 polymorphism with that of the clinicopathological parameters was also analyzed. No significant association was seen in any of the parameters (*P* \> 0.05) with the said polymorphism \[[Table 2](#T2){ref-type="table"}\].

###### 

Association between PTPN22 1858 C/T polymorphism and various clinical parameters of patients with GD
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D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Apart from Major Histocompatibility Complex, PTPN22 locus is a potent risk factor associated with several autoimmune diseases. LYP protein encoded by *PTPN22* gene is expressed exclusively by the cells of immune system.\[[@ref15]\] In the coding region of this gene, a single-base change within a polyproline binding motif (from amino acid arginine to tryptophan) has been associated with Type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Hashimoto\'s thyroiditis, and GD.\[[@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22]\]

In this case--control study, we investigated the association between *PTPN22* gene 1858 C\>T polymorphism and GD in Kashmiri population. Among patients with GD, the frequencies of *PTPN22* 1858 CC and CT genotypes were 97.78 and 2.22%, respectively, and TT genotype seen in none. Among healthy controls, *PTPN22* 1858 CC genotype was seen in all and none had CT and TT genotypes. Genotypic and allelic frequencies of the *PTPN22* 1858 polymorphism in cases and controls were not significantly different (*P* \> 0.05) \[[Table 1](#T1){ref-type="table"}\]. The individuals harboring T allele of the *PTPN22* C1858T gene SNP have been shown to be more susceptible to development of GD in British and Polish Caucasians.\[[@ref11][@ref12][@ref16][@ref23]\] Further, a meta-analysis showed association of *PTPN22* 1858T allele with rheumatoid arthritis, systemic lupus erythematosus, GD, and type 1 diabetes in Caucasians.\[[@ref24]\] It has been proposed that the disease-associated T allele encodes a protein that does not bind to the protein tyrosine kinase Csk and may therefore cause general hyperresponsiveness of T cells.\[[@ref6]\] In our study only, 3 out of 135 GD cases had CT genotype, while T allele was completely absent in controls. Our results are consistent with the study in Japanese populations by Ichimura *et al*.,\[[@ref14]\] documenting an absence of the T allele in all the patients and healthy controls. Also, several other reports have shown that *PTPN22* T variant is absent in patients with GD, type 1 diabetes, rheumatoid arthritis as was in healthy population,\[[@ref25][@ref26][@ref27]\] implying that *PTPN22* gene polymorphism shows ethnic differences. The results of the present study suggest that 1858 C/T SNP may be of little importance in our patient population with GD.

Limitations {#sec2-6}
-----------

Small sample size might be a limitation in our study. We suggest more such studies with a larger sample size to be conducted because of rarity of *PTPN22* 1858 T allele in Kashmiri population.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

*PTPN22* 1858 C/T polymorphism does not show an association with GD in Kashmiri population.
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